Key result
The G/C genotype of the Gly389Arg polymorphism of the β1-adrenergic receptor gene significantly reduced the risk of atrial fibrillation development in patients with heart failure (OR 0.14).
Why the study?
The study was conducted to examine the relationship between gene polymorphisms of the beta-adrenoreception system and the risk of atrial fibrillation in patients with heart failure.
Are beta-adrenergic receptor gene polymorphisms associated with the risk of atrial fibrillation in patients with heart failure?
Observational (n=286)
Single-blind
No
Are beta-adrenergic receptor gene polymorphisms associated with the risk of atrial fibrillation in patients with heart failure?
Effect estimate: OR 0.14 (95% CI 0.03-0.61)
p-value: p=0.0043
Congenital genetic differences in beta-adrenoreception pathways, specifically the G/C genotype of the Gly389Arg polymorphism, may be associated with a reduced risk of atrial fibrillation in heart failure patients.
Hypothesis-generating for β1-receptor genotyping in HF-related AF; should not yet change practice.
Objective: to study the relationship of gene polymorphisms of the b-adrenoreception system with the risk of atrial fibrillation in patients with heart failure. and methods. 286 patients with heart failure on the background of post-infarction cardiosclerosis were included. Of these, 25 (8.7 %) patients had the atrial fibrillation. The genotyping was performed using 4 polymorphisms (Gly389Arg of the b1-adrenoreceptors gene, Ser49Gly of the b1-adrenoreceptors gene, Gln27Glu of the b2-adrenoreceptors gene and Ser275 of the b3-subunit of G-protein gene) using the polymerase chain reaction. The genetic and epidemiological analysis was carried out using the SNPStats program.. Patients with heart failure with the G / C genotype of Gly389Arg polymorphism of the b1-adrenoreceptors gene have a lower risk of developing atrial fibrillation (OR=0.14 (0.03–0.61), p=0.0043, co-dominant model of heredity). data on a decrease in the risk of atrial fibrillation in patients with heart failure and with the G/C genotype Gly389Arg polymorphism of the b1-adrenoreceptors gene are also confirmed in the overdominant (OR=0.15 (0.03–0.64), p=0.0012), as well as in the dominant (OR=0.23 (0.08-0.69), p=0.0029) and the log-additive (OR=0.40 (0.17-0.94), p=0.019) models.. The results allow us to conclude that congenital genetic differences in the pathways of b-adrenoreception can be associated with the development of atrial fibrillation in patients with heart failure
No takes yet. Share an insight, caveat, or question.
Pyvovar et al. (2019) conducted an observational in Heart failure (n=286). G/C genotype of the Gly389Arg polymorphism of the β1-adrenergic receptor gene vs. G/G and C/C genotypes was evaluated on Risk of atrial fibrillation development (OR 0.14, 95% CI 0.03-0.61, p=0.0043). The G/C genotype of the Gly389Arg polymorphism of the β1-adrenergic receptor gene significantly reduced the risk of atrial fibrillation development in patients with heart failure (OR 0.14).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: